Patient P-02363
Therapy response
Stable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
71%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 70 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 78 GI-04 recommended — GI Support Protocol GI-04
- Day 79 Patient accepted — Started GI-04 in the companion
- Day 86 ME-01 recommended — Monitoring Escalation ME-01
- Day 87 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 87 Patient accepted — Started ME-01 in the companion
- Day 90 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 93 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 70.
Primary contributors, last 14 days
- GI instability-10
- Treatment adherence-8
- Nutritional resilience+5
- Toxicity+5
- Inflammatory activity-2
What helped?
- GI Support Protocol GI-04Day 78Result: symptom burden −19%
- Monitoring Escalation ME-01Day 86Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 51 and rising
- WearableSleep 5.2 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 56
- WearableHRV 31 ms, trending down
- Autonomic recovery ↑45
- WearableResting HR 74 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 55
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.5 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 28 ms
- Sleep
- 5.3 h
- Steps
- 4,804
- Resting HR
- 77 bpm
Daily log: GI score 51, nutritional resilience 43, adherence 44.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.